Vicarious Surgical price target lowered to $10.50 from $12 at Piper Sandler

Piper Sandler lowered the firm’s price target on Vicarious Surgical (RBOT) to $10.50 from $12 and keeps a Neutral rating on the shares. The firm notes Vicarious Surgical announced Q3 results with adjusted EPS below the Street’s target. Looking ahead to the rest of 2024, the company reiterated its full year 2024 cash burn guidance of about $50M. The company also remains on track for the V1.0 system integration within the next few weeks, and still plans to treat its first patient within the next 12-months, Piper adds.